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Abstract Onconephrology is an emerging medical sub-
specialty focused on the numerous interconnections between
cancer and kidney diseases. Patient with malignancies
commonly experience kidney problems including acute
kidney injury, tumor lysis syndrome, fluid and electrolyte
disorders and chronic kidney disease, often as a consequence
of the anti-cancer treatment. Conversely, a number of
glomerulopathies, tubulopathies and vascular renal diseases
can early signal the presence of an underlying cancer. Fur-
thermore, the administration of immunosuppressive drugs,
especially cytotoxic drugs and calcineurin inhibitors, may
strongly impair the immune response increasing the risk of
cancer. The objective of this review article is to: (i) discuss
paraneoplastic glomerular disease, (ii) review cancer as an
adverse effect of immunosuppressive agents used to treat
glomerulopathies, and (iii) in the absence of international
approved guidelines, propose a screening program based on
expert opinion aimed at guiding nephrologists to early detect
malignancies during their clinical practice.
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Introduction
Onconephrology is a new discipline that covers the many
interrelations between cancer and kidney diseases [1].
Acute kidney injury, tumor lysis syndrome, fluid and
electrolyte disorders and chronic kidney disease are fre-
quent complications of anti-cancer treatment, particularly
in elderly patients [2]. On the other hand, a number of
glomerular, tubulo-interstitial and vascular renal diseases
can be associated with solid or hematopoietic malignancy
[3] and may often represent the first clinical manifestation
of an underlying cancer. This is of particular concern for
the nephrologist, not only because it can lead to delayed
diagnosis of cancer but also because incorrect diagnosis
may lead to harmful treatment. Lastly, an already existing
occult cancer that is recognized too late may be wrongly
attributed to the immunosuppressive therapy used to treat
the original, presenting renal disease.
In this article, we will discuss the most frequent
glomerular diseases that are caused by cancer (paraneo-
plastic glomerulopathies), the oncogenic role of immuno-
suppressive therapy, and screening recommendations for
detecting cancer in patients with glomerulopathies.
Paraneoplastic glomerulopathies
The term paraneoplastic syndrome was introduced to indi-
cate the clinical manifestations that are not directly related to
tumor burden, invasion, or metastasis but are caused by the
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secretion of tumor cell products, such as hormones, growth
factors, cytokines and tumor antigens [4]. There is experi-
mental evidence showing that tumor-bearing animals can
develop proteinuria and glomerular lesions with abundant
immunoglobulin (Ig)G deposits in the glomeruli and
effacement of podocyte foot processes [5]. In 1922, Gal-
loway introduced the concept of paraneoplastic glomeru-
lopathy [6], but the first original study highlighting the
association between cancer and nephrotic syndrome (NS)
was published in 1966 by Lee and colleagues [7].
It is difficult to assess the true prevalence of cancer-
related glomerulopathies due to a number of confounding
factors such as: (i) potential detection bias (e.g., patients
with membranous nephropathy are likely to be more
aggressively screened for cancer); (ii) demographic char-
acteristics of the population (e.g., both membranous
nephropathy and cancer occur more frequently in the
elderly and/or in heavy smokers); and (iii) most of the
agents used to treat glomerular disease are potentially
oncogenic drugs, which may themselves lead to subsequent
malignancies [4]. Thus, it is not surprising that little
information about the prevalence of paraneoplastic
glomerulopathies is available.
The prevalence of paraneoplastic glomerulopathies has
been evaluated by a few retrospective, and a few
prospective, studies. Pai and colleagues [8] selected 120
patients with different types of primary glomerulonephritis
(GN) and found that 17 (14.1 %) had cancer. Among them,
six were diagnosed at the time of biopsy, four in the first
year, and seven after 1 year. The histological renal diag-
noses included membranous nephropathy (MN), membra-
noproliferative GN (MPGN), crescentic GN, and focal
segmental glomerulosclerosis (FSGS). Cancer was detected
by screening that included a chest x-ray and abdominal
ultrasound [8]. In the Tromso study, initially aimed at
combating the high mortality of cardiovascular disease in
Norway and then extended to investigate the causes and
possible prevention of other chronic diseases, Jorgensen
and colleagues examined the possible relationship between
cancer and albuminuria in a prospective cohort of 5425
participants with no history of diabetes, cancer or
macroalbuminuria. The participants with an albumin-to-
creatinine ratio in the highest quintile were 8.3 and 5.4
times more likely to develop bladder and lung cancer,
respectively, than those in the lowest quintile [9]. Saitoh
and colleagues analyzed the risk of GN in 125 patients with
myelodysplastic syndrome. Five patients (4 %) had
glomerular disease and three (2.4 %) had nephrotic syn-
drome [10]. Birkeland and colleagues published a retro-
spective study that analyzed 1958 patients found by
matching the Danish renal biopsy registry with the onco-
logical registry [11]. None of the participants with renal
disease had cancer at the time of biopsy. These patients had
histological renal diagnoses of different types of primary
GN with extra or endocapillary proliferation and sclerosis.
During follow-up, 102 patients developed cancer (5.2 %).
Cancer localization in males included lung, skin, lymphatic
and hematopoietic tissue, with diagnoses of MN, MPGN,
and proliferative endocapillary GN at renal biopsy. In
women, cancer localization included the gastrointestinal
tract and lymphatic and hematopoietic disorders with a
prevalence of minimal change disease (MCD) at renal
biopsy. The risk of cancer among patients with biopsy-
proven GN was 2.5 and 3.5 times higher than in the general
population at 1 and 2 years, respectively. However, at
5 years or more after biopsy the risk of cancer was the
same [11]. Rihova and colleagues selected 129 patients
with a histological diagnosis of MN and found 8 patients
with tumors (6.2 %). Five were identified at the time of
biopsy, which was accompanied by chest x-ray, abdominal
ultrasound scan, serum tumor markers and mammography
in patients[50 years of age. The most commonly found
tumors were affecting lung, colon, and prostate [12].
Lefaucheur and colleagues selected 240 patients with a
histological diagnosis of MN. Among them, 24 patients
(10 %) had cancer, which was more often localized in the
lung, prostate and stomach [13]. Twenty-one cases of
cancer were detected at the time of renal biopsy, the
remaining three within 1 year post-biopsy. There were no
differences between men and women, but a higher inci-
dence was reported in the elderly and in heavy smokers
[13] (Table 1).
An association between cancer and glomerular disease is
possible and it is probably related to altered immune
responses in the presence of a malignancy [14]. Studies on
murine models documented that T-helper 2 polarization
has an important role in the development of thymoma-
associated glomerular lesions in MCD and FSGS and an
overexpression of interleukin (IL)-13, a T-helper 2 cyto-
kine, induces MCD in rats [15, 16]. Furthermore, it is
known that tumoral antigens can induce anti-tumor anti-
bodies and consequently immune complex deposition in
the glomeruli (sub-epithelial deposition in MN) [17, 18].
However, the diagnosis of paraneoplastic glomerulopathy
is problematic due to the possible biases listed above and to
the difficulty in identifying the tumor when GN is diag-
nosed (delayed diagnosis of malignancy). The sequence of
events in the patient’s clinical history can help in differ-
entiating a paraneoplastic glomerulopathy from malig-
nancy caused by treatment of the GN. After cancer is
diagnosed, a careful retrospective investigation of the
radiological findings can also help in detecting small
lesions that could have been misinterpreted. It is important
to establish whether GN occurred in the presence of
malignancy since ablation of cancer may result in remis-
sion of glomerular lesions.
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Although MN is the most frequent GN associated with
solid tumors, and MCD is the most frequent glomerular
disease associated with Hodgkin lymphoma, many excep-
tions exist [19]. In fact, other forms of glomerular diseases,
including FSGS, MPGN, IgA nephropathy (IgAN) and
rapidly progressive GN may also be associated with solid
tumors. On the other hand, not only MCD, but also MN,
MPGN, FSGS and IgAN may be associated with hemato-
logic malignancies [14]. Thus, specific tumors are not
necessarily associated with a specific type of GN.
Oncogenic role of immunosuppressive therapy
Any form of treatment that reduces immune surveillance
may increase the risk of cancer. However, the role of single
immunosuppressive drugs in increasing cancer risk is still
under debate.
Glucocorticoids are not classified as oncogenic drugs
[20]. However, these agents blunt the capacity of the
immune system to mount a response by interfering with
inflammation [21], inhibiting antigen presentation, sup-
pressing cell-mediated immunity and partially inhibiting
humoral immunity [22]. Thus, it is likely that the duration
and dosage of glucocorticoid treatment would lead to a
state of immunodeficiency, which might facilitate a faster
development of a pre-existing neoplasia.
Alkylating agents are derived from nitrogen mustards. In
clinical nephrology, the most frequently used alkylating
agents are cyclophosphamide and chlorambucil. They
share the ability to contribute alkyl groups to biologically
active macromolecules such as DNA. Both cyclophos-
phamide and chlorambucil are classified as carcinogenic
drugs. Two types of cancer are especially frequent with
cyclophosphamide administration: bladder cancer and
hematological malignancies. The development of bladder
cancer is likely related to the chronic mucosal inflamma-
tion and irritation caused by acrolein, an inactive metabo-
lite of cyclophosphamide, and/or to a direct oncogenic
effect of cyclophosphamide or its metabolites on the
urothelium. The risk of bladder cancer seems to be related
to the cumulative dose of cyclophosphamide. In a Danish
report, the standardized incidence ratio was found to be 9.6
times greater for patients who received[ 36 g of
cyclophosphamide as compared to those who received
lower doses or no cyclophosphamide at all [23]. To prevent
the possible development of bladder carcinoma, abundant
fluid intake and sodium 2-mercaptoethanesulphonate
(MESNA) should be prescribed concomitantly. MESNA
binds to acrolein and prevents direct contact with the
urothelium. It is currently recommended together with
hydration in patients who receive intravenous high-dose
cyclophosphamide [24]. However, some patients may
develop hemorrhagic cystitis despite treatment with
MESNA, because cyclophosphamide may cause two waves
of apoptosis, one being independent of MESNA. In these
patients, the anti-oxidant acrolein may be added to
MESNA to reinforce a protective effect [25]. An increased
risk of hematological malignancies with the prolonged use
of cyclophosphamide has been reported; in patients with
systemic lupus erythematosus, the risk of lymphoma was
found to be higher with exposure to cyclophosphamide and
high cumulative doses of steroids [26]. In granulomatosis
with polyangiitis, a[36 g dose of cyclophosphamide
resulted in a standardized incidence ratio of 59 for acute
myeloid leukemia as compared to the general population
[23]. As a prudent recommendation when using
cyclophosphamide in a patient with GN, the cumulative
dose should not exceed 360 mg/kg, i.e., 2 mg/kg/day for
6 months or 1 mg/kg/day for 12 months.
A marked increase in acute leukemia has been observed
with long-term chlorambucil treatment in patients with
polycythemia vera [27] or ovarian cancer [28]. Little
information about the oncogenic effect of chlorambucil in
renal patients is available. In a study of meta-analysis on
1504 children with idiopathic NS who received
cyclophosphamide or chlorambucil, 14 (0.9 %) cases of
malignancy were reported. In those patients, high doses of
either one of the two alkylating agents were used. This
meta-analysis also showed that chlorambucil has higher
rates of severe side effects and should be considered a
second-line drug [29]. A review of the data from three
randomized trials in adults with idiopathic MN showed that
the risk of cancer for patients who were treated with
chlorambucil for B3 months was similar to that for the
general population [30]. Although there is no clear cut-off
for the doses of chlorambucil, we recommend not
exceeding daily doses of 0.1–0.2 mg/kg and not prolonging
treatment for more than 3 months.
Azathioprine is a thiopurine derived from 6-mercap-
topurine. Azathioprine is a prodrug that is metabolized to
thioinosinic acid and 6-thioguanine. These metabolites
interfere with the de novo, and salvage, pathways of purine
synthesis, respectively. The notion that long-term treatment
with azathioprine can favor the development of neoplasia
in organ transplant recipients has been known for many
years [31, 32]. On the other hand, little information is
available about the oncogenic effects of azathioprine in
autoimmune diseases. A systematic review on the use of
azathioprine in multiple sclerosis suggested that the risk of
cancer was related to treatment duration of 10 years and a
cumulative dose above 600 g [33]. The risk of cancer with
azathioprine in inflammatory bowel disease has been dif-
ferently estimated. Data from a Danish registry reported
J Nephrol
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that azathioprine use was associated with increased risk of
lymphoid tissue cancer and urinary tract cancer, the rate
ratios being 2.40 and 2.84, respectively [34]. Sporadic
cases of cancer in patients given azathioprine because of
glomerulonephritis have been reported, but no systematic
reviews are currently available.
Mycophenolic acid (MPA) inhibits the enzyme inosine
monophosphate dehydrogenase by which guanine is syn-
thesized from inosine. As a consequence the de novo
pathway of purine synthesis is inhibited. Unlike azathio-
prine MPA is not incorporated into DNA. Since activated
lymphocytes rely more than other cells on de novo path-
ways, T and B cells are preferentially affected by MPA,
which causes an accumulation of lymphocytes at the G1–S
phase of the cell cycle. There are two salts of MPA,
mycophenolate mofetil (MMF) and an enteric-coated for-
mulation of sodium mycophenolate. Although MPA may
theoretically favor an increased risk of tumor through
impairment in the immune surveillance, it has been shown
to have antiproliferative activity against leukemia and
lymphoma and an anti-tumor effect against colon and
prostate cancer. In renal transplant recipients, the use of
mycophenolate is associated with a reduced incidence of
lymphoproliferative disorders [33, 35, 36].
Calcineurin inhibitors (CNI) are drugs that can inhibit
the activation of T cells by interfering with the synthesis
of IL-2 and other cytokines. Both cyclosporine and
tacrolimus can increase the risk of cancer in transplant
recipients [32]. In comparison with azathioprine, patients
treated with CNI seem to develop neoplasias earlier and
to be more susceptible to lymphoproliferative disorders
and Kaposi sarcoma [37]. The risk of cancer after
exposure to CNI depends on the dosage and duration of
treatment. There are no data concerning the prevalence
of cancer in CNI-treated patients with GN. It is possible
that the risk of cancer may be relatively low, since
administration of either cyclosporine or tacrolimus rarely
exceeds 2 years in patients with glomerular diseases.
When treatment is longer the administered doses are
usually low.
In summary, any type of therapy weakening the immune
response may theoretically render a patient more suscep-
tible to cancer. The risk is higher with the use of car-
cinogenic drugs, and is also related to the intensity of
immunosuppression and duration of immunosuppressive
treatment. However, differential diagnosis between a
paraneoplastic glomerulopathy and cancer caused by GN
treatment can be difficult, mainly because GN can precede
the identification of an underlying malignancy by months
or even years. In either case, surveillance and a high degree
of clinical suspicion for underlying cancer should be
maintained in the patient with GN.
Oncological screening for paraneoplastic
glomerulopathies
How and whether patients with an established diagnosis of
glomerular disease should be screened for cancer is still a
matter of discussion among nephrologists. Currently, no
guidelines have been recommended by renal scientific
societies. We feel that a focused work-up would allow us to
identify the majority of cancers in these patients. It should
include a complete family and patient history, a careful
physical examination including testicular or breast exami-
nation, and some investigations that are routinely prescribed
in hospitalized patients such as: complete blood count, pro-
thrombin (PT), partial thromboplastin time (PTT), elec-
trolytes, uric acid, and renal and liver function tests, baseline
viral titers, chest x-ray, renal and urinary tract ultrasonog-
raphy, careful testing of urine sediment and a search for fecal
occult blood. In the absence of a specific suspicion of cancer,
oncological screening is usually the same as it is for the
general population (except for chest computed tomography
[CT] in heavy smokers). The work-up could be more
extensive if the patient is older than 60 years of age, is a
heavy smoker, and/or has nephrotic syndrome. This work-up
should include gastroscopy, colonoscopy, gynecological
examination, chest CT. A search for malignant cells in the
urine may be added to detect urothelioma in patients with
frequent use of analgesic drugs.
Although any subtype of primary or secondary GN may
be associated with cancer, the risk of solid tumors is more
frequent in patients with MN, especially in those older than
60 years of age. As pointed out by several investigators,
the diagnosis of MN often precedes that of the associated
cancer, sometimes even by years [13, 38]. Therefore, work-
up for malignancy in MN should also be initiated in
patients with non-nephrotic proteinuria. Some clues may
suggest the presence of cancer in a patient with MN,
although there are no specific signs or symptoms. When
examining the renal biopsy, mesangial or sub-endothelial
electron dense deposits are not seen in idiopathic MN and
should raise the suspicion of a secondary form of MN. The
presence of inflammatory cells is rare in idiopathic MN,
while it is frequent in cancer-associated MN. More than 8
leukocytes per glomerulus showed 75 % sensitivity and
92 % specificity for identifying cancer-associated MN
[13]. Immunofluorescence microscopy shows that IgG4
deposits are usually seen in idiopathic MN, while deposits
of IgG1, IgG2 or IgG3 are more frequent in cases of sec-
ondary MN, including those associated with cancer [39].
Circulating anti-phospholipase A2 receptor 1 (anti-
PLA2R1) antibodies are frequently seen in idiopathic MN
[40], while they are rarely found in cancer-associated MN
[41]. Accordingly, an intensive search for cancer should be
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carried out in MN patients without anti-PLA2R1 antibod-
ies, with prevailing IgG1/IgG2 deposits, or with more than
eight inflammatory cells per glomeruli at renal biopsy.
Since it is not always possible to exclude the casual asso-
ciation between cancer and glomerular disease, an accurate
report of the renal biopsy, including tissue IgG subclasses
and number of glomerular inflammatory cells is crucial.
However, Qin and colleagues reported that 3 tumor-asso-
ciated MN patients positive for anti-PLA2R1 antibodies
had persistent or relapse of proteinuria despite resection of
the tumor [41], suggesting that the presence of anti-
PLA2R1 antibodies may indicate their pathogenic role and
a casual association between cancer and MN.
Thromboembolic disease is another clinical factor that
should raise a suspicion of neoplasia in MN. It is also a
well-known complication associated with the nephrotic
syndrome, especially when the serum albumin concentra-
tion is below 2.8 g/dl [42, 43]. The presence of cancer
increases the risk of thromboembolism. About 25 % of
patients with cancer-associated MN experienced a throm-
botic event [44]. Therefore, if a patient with nephrotic
syndrome caused by MN also has deep venous thrombosis
or a thromboembolic event, it is plausible, though unpro-
ven, that he/she will present a higher probability of having
cancer-associated MN. Considering the extraordinary
diversity of the neoplasia-MN connection, the search for an
underlying neoplasia is limited to screening for the most
common types of cancer when no signs or symptoms are
present. Among solid tumors, lung, colon, breast, prostate,
uterus and stomach cancers are the most frequently
observed in patients with MN.
Hematological malignancies, including leukemia and
lymphoma, can also occur in patients with MN or other
types of glomerular diseases, but they are more frequent in
patients with minimal change disease. Full screening for
hematological malignancy is warranted in patients with
unexplained anemia, monoclonal peak at electrophoresis,
hepatomegaly or splenomegaly, enlarged lymph nodes,
night sweats, and fever or weight loss. Screening should
include a bone marrow biopsy, total body CT scan or
positron emission tomography scan.
However, only few centers adopt specific screening for
cancer in patients with glomerulopathies. A multi-center
analysis of the treatments used in patients with MN was
carried out in 15 renal units in Piedmont, Italy [45]. All the
centers performed cancer screening, but there were consid-
erable differences in the screening programs. All centers
collected a detailed clinical history and carried out physical
examination, chest x-ray and complete abdominal ultra-
sound for each patient. Serological cancer biomarkers were
checked in 13 centers, the search for occult blood in the stool
was done in 11 centers, while in 9 centers colonoscopy was
performed and women underwent breast examination and
mammography. Six centers performed gastroscopy, while 5
carried out Papanicolauo (Pap) tests for cervical screening.
The most frequently observed tumors were in the kidney,
stomach, lung, prostate and colon. This survey from an
Italian region in which there is close cooperation among
renal units confirms the importance of cancer screening but
also highlights the need for clear guidelines to avoid differ-
ences in the screening programs [45].
Few data are available on the screening policies used for
GN other than MN. The renal registry of the G. Brotzu
Hospital in Cagliari, Italy showed that 163 patients with
nephrotic syndrome and biopsy-proven GN underwent
‘‘full’’ screening for cancer from January 1982 to January
2012 (personal communication). The ‘‘full’’ screening
performed on all patients included: tumor bio-markers
(Ca125, CEA, Ca19.9, Ca15.3, alpha fetoprotein, prostate-
specific antigen), stool for occult blood, chest x-ray,
complete abdominal ultrasound, gastroscopy, total body
CT, colonoscopy, mammography, Pap test for cervical
screening and the search for urinary neoplastic cells.
Malignancy was discovered in 3 patients (1.8 %). After a
median follow-up of 5.7 years (range 1 month–21 years),
nine other patients (5.6 %) developed cancer. In total, of
the 12 malignancies, seven occurred among 95 patients
with MN, and five among 55 patients with MCD. No case
of cancer was detected among the six patients with FSGS
or the seven with MPGN. The types of cancer are shown in
Table 2. We compared the 151 patients without cancer to
the 12 patients with cancer by demographic, clinical and
renal function data (Table 3). The only significant differ-
ences were older age and lower creatinine clearance in
patients with cancer. During follow-up, no differences were
observed between the two groups with regard to Kaplan–
Meier life survival curves (Fig. 1).
Since nephrotic syndrome is the clinical renal syndrome
that is most often associated with malignancy, we suggest
Table 2 Incidence of neoplasms in 163 patients with nephrotic
syndrome undergoing oncological screening at the Renal Unit of the
G. Brotzu Hospital in Cagliari, Italy
Cancer No. patients Percentage of patients (%)
Breast 2 1.22
Duodenum 2 1.22
Colon-rectum 2 1.22
Basal-cell 1 0.61
Bladder 1 0.61
Kidney 1 0.61
Lung 1 0.61
Thymus 1 0.61
Thyroid 1 0.61
Total 12 7.3
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adopting a screening program for nephrotic patients
(Table 4). When cancer is detected, the primary treatment
must be focused on the cancer in all cases [46].
For how long should a patient
with glomerulopathy be screened for cancer?
Even in the case of a paraneoplastic glomerulopathy,
cancer may be clinically discovered years after the diag-
nosis of renal disease. Indeed, many tumors require years
or even decades before exhibiting clinical symptoms. In the
meantime, these hidden tumors may release antigens that
trigger the production of antibodies leading to the forma-
tion of circulating immune complexes or renal deposits of
antigens that react with antibodies resulting in local for-
mation of immune complexes. Whatever the mechanism,
the deposition of immune complexes may cause inflam-
mation, release of reactive oxygen species and complement
activation, possibly leading to glomerular damage.
However, besides the few cases of late recognition of
cancer in a paraneoplastic glomerulopathy, one should take
into account that glucocorticoids, immunosuppressive
agents, or biologic medications that are used to treat
chronic GN strongly interfere with the immune response
and can favor the development of malignancy or may
themselves be carcinogenic [11]. In the absence of guide-
lines, we recommend that patients who have undergone or
undergo long-term immunosuppression should receive
complete screening for cancer every 5 years if
aged\50–60 years, or every 3 years if they are older.
Conclusion
Evidence from the literature and from clinical practice sug-
gests that a strong pathogenetic link exists between GN and
malignancies. The administration of powerful immunosup-
pressive drugs, especially cytotoxic drugs and calcineurin
inhibitors, may strongly impair the immune response and
increase the oncogenic risk. Setting up appropriate screening
programs is thus recommended, especially in elderly patients,
in those with nephrotic syndrome and in those who undergo
long-term immunosuppressive therapy. In the absence of
Table 3 Baseline
characteristics of 163 patients
with nephrotic syndrome
undergoing oncological
screening at the Renal Unit of
the G. Brotzu Hospital in
Cagliari, Italy
Characteristics No. patients Cancer Control p value
No. 163 12 151
Male 97 58.3 58.7 0.781
Female 66 41.7 41.3 0.781
Age (years) 54 63 53 0.049
Proteinuria (g/24 h) 7 8.2 6.3 0.429
Cholesterol (mg/dl) 304.5 301 327 0.795
Serum albumin (g/dl) 2.4 2.3 2.4 0.570
SCr (mg/dl) 1 1.1 1.0 0.680
Creatinine clearance (ml/min) 96.3 67.8 99.5 0.046
eGFR-CKD-Epi (ml/min) 82 71 80.1 0.351
eGFR-MDRD 76 66 74 0.458
Mean arterial pressure (mm/hg) 106 110 104.6 0.305
Follow-up (months) 72 94 72
The bold values indicate p values less than 0.05
SCr serum creatinine, eGFR estimated glomerular filtration rate, CKD-Epi chronic kidney disease epi-
demiology collaboration formula, MDRD modification of diet in renal diseases formula
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Fig. 1 Kaplan-Meier cumulative life survival curves of patients with
nephrotic syndrome (NS) and cancer (red/dashed line) and patients
with nephrotic syndrome alone (black/continuous line) in the Renal
Unit of the G. Brotzu Hospital in Cagliari, Italy
J Nephrol
123
internationally approved guidelines and evidence-based
indications, we propose a screening program based on expert
opinion, in an effort to help the nephrologist in the early
detection of malignancies during clinical practice.
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Table 4 Proposed oncological screening of patients with nephrotic syndrome and of patients undergoing long-term immunosuppressive therapy
Screening levels Proposed procedures
First level analyses Collection of family and patient’s complete clinical history
Careful physical examination including:
Skin examination ? if suspicious, dermatoscopy
Testicular palpation in young males ? if positive, testicular US
Breast palpation in women ? if suspicious, move to a second
level test
Routine investigations:
Complete blood count, PT, PTT, electrolytes, uric acid, and renal
and liver function tests, baseline viral titers
Chest x-ray
Neck US ? full abdomen (including renal and urinary tract) US
Fecal occult blood search ? if positive,
gastroscopy ± colonoscopy
Second level analyses (if first level analyses are negative) Women
Gynecological examination ? if suspicious, transvaginal US
Pap test
Breast US ± mammography
If unexpected monomorphic hematuria ? cystoscopy
Men
Urological examination (including digital rectal examination)
PSA dosage and, if one or both suspicious? trans-rectal prostate
US and biopsy
If unexpected monomorphic hematuria ? cystoscopy
Third level analyses (if first and second level analyses are negative), only
in high risk patients (one or more of the following):
1) Heavy smokers
2) Alcohol abusers
3) Older than 60 years/old
4) Thromboembolic events
5) Long term immunosuppressive therapy
6) HBV and/or HCV and/or HIV infection
Colonoscopy
Computed tomography of the chest
Search for malignant cells in urine and cystoscopy
Contrast-enhanced liver US in cirrhotic patients
ENT examination ± upper respiratory tract fibroendoscopy
Consider cautiously a few specific tumor markers (e.g., alpha1-
fetoprotein in HBV and/or HCV-positive patients)
Renal pathology clues (only for MN) High suspicion of secondary MN in case of:
Detection of mesangial or sub-endothelial electron dense deposits
More than eight leukocytes per glomerulus
Prevalence of IgG1, IgG2 or IgG3 deposits at
immunofluorescence
Absence of anti PLA2R1 antibodies
US ultrasound, PT prothrombin, PTT partial thromboplastin time, Pap papanicolauo, PSA prostate specific antigen, HBV hepatitis B virus, HCV
hepatitis C virus, HIV human immunodeficiency virus, ENT ear-nose-throat, MN membranous nephropathy, IG immunoglobulin, PLA2R1
phospholipase A2 receptor 1
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